CLINICAL_TRIALS withdrawal · 2015-01-12

Clinical Trial Update: A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer [Phase 2]

Pfizer-sponsored Phase 2 study for patients with advanced EGFR-mutant non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC | Phase 2 | Status: WITHDRAWN